Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Sep 23;60(10):6393-7.
doi: 10.1128/AAC.01125-16. Print 2016 Oct.

In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species

David R Snydman  1 , Nilda V Jacobus  2 , Laura A McDermott  2
Affiliations
Multicenter Study

In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species

David R Snydman et al. Antimicrob Agents Chemother. .

Abstract

We evaluated the in vitro activity of imipenem-relebactam (imipenem-MK7655) against 451 recent clinical isolates within the Bacteroides group and related species. Relebactam did not enhance or inhibit the activity of imipenem against Bacteroides fragilis or other Bacteroides species. No synergistic or antagonistic effect was observed. The MICs of imipenem-relebactam were equal to or within one dilution of the MICs of these isolates to imipenem.

PubMed Disclaimer

References

    1. Hirsch EB, Ledesma KR, Chang K-T, Schwartz MS, Motyl MR, Tam VH. 2012. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 56:3753–3757. doi:10.1128/AAC.05927-11. - DOI - PMC - PubMed
    1. Castanheira M, Mendes RE, Woosley LN, Jones RN. 2011. Trends in carbapenemase-producing E. coli and Klebsiella spp. from Europe and the Americas: report from SENTRY antimicrobial surveillance programme (2007–09). J Antimicrob Chemother 66:1409–1411. doi:10.1093/jac/dkr081. - DOI - PubMed
    1. Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Chen K, Brown M, Losada M, Pedley A, Kartsonis N, Paschke A. 2015. A phase 2 study to evaluate the efficacy & safety of relebactam (REL) + imipenem/cilastatin (IMI) vs IMI alone in subjects with complicated intra-abdominal infection (cIAI), abstr F-269. Abstr Intersci Conf Antimicrob Agents Chemother, San Diego, CA, 17 to 21 September 2015.
    1. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJC, Harrell L, Jenkins S, Newton D, Pierson C, Rihs J, Yu VL, Venezia R, Iannini P, Finegold SM, Gorbach SL. 2010. Lessons learned from the anaerobe survey: historical perspectives and review of the most recent data (2005–2007). Clin Infect Dis 50(Suppl 1):S26–S33. doi:10.1086/647940. - DOI - PubMed
    1. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJC, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Yu VL, Rihs J, Gorbach SL. 2007. National survey on the susceptibility of B. fragilis group: report and analysis of trends from 1997–2004 in the United States. Antimicrob Agents Chemother 51:1649–1655. doi:10.1128/AAC.01435-06. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources